[
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)",
    "summary": "Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)",
    "url": "https://finnhub.io/api/news?id=0bc9e884af1c60b1fa876c5abf2a3a46f8142e221c8098029bcdc0a8f0950fc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748547727,
      "headline": "Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)",
      "id": 134859012,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0bc9e884af1c60b1fa876c5abf2a3a46f8142e221c8098029bcdc0a8f0950fc9"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03",
    "summary": "Presenter SpeechCourtney Breen All right. So we might kick off our conversation with Merck today. My name is Courtney Breen. I am the U.S. biopharma analyst here at Bernstein. I am very privileged",
    "url": "https://finnhub.io/api/news?id=e7be62df8835c4a3155178efec3a1a87d96109ee499052e8fa335a97d93eca11",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748539217,
      "headline": "Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03",
      "id": 134850569,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Presenter SpeechCourtney Breen All right. So we might kick off our conversation with Merck today. My name is Courtney Breen. I am the U.S. biopharma analyst here at Bernstein. I am very privileged",
      "url": "https://finnhub.io/api/news?id=e7be62df8835c4a3155178efec3a1a87d96109ee499052e8fa335a97d93eca11"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=0606eca4222b6bac1ec4363ce5e0bcb5f0f75f65375a4bfb83ab3dac667f0d26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748523614,
      "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 134812091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=0606eca4222b6bac1ec4363ce5e0bcb5f0f75f65375a4bfb83ab3dac667f0d26"
    }
  },
  {
    "ts": null,
    "headline": "Moderna suffers a $750 million loss from NIH funding cut",
    "summary": "Moderna's pipeline potential is being squeezed by the Trump administration.",
    "url": "https://finnhub.io/api/news?id=42abd50042c44d5a44298f46253caac563a29059aee1a302f60ca43962188a95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748518580,
      "headline": "Moderna suffers a $750 million loss from NIH funding cut",
      "id": 134812095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Moderna's pipeline potential is being squeezed by the Trump administration.",
      "url": "https://finnhub.io/api/news?id=42abd50042c44d5a44298f46253caac563a29059aee1a302f60ca43962188a95"
    }
  },
  {
    "ts": null,
    "headline": "Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., May 29, 2025--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies has been",
    "url": "https://finnhub.io/api/news?id=725bba216f3629ddc9248ae42d16a34e476c6b9e6f9a5b02d1ebe1ade0fced70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748516400,
      "headline": "Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn",
      "id": 134812098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., May 29, 2025--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies has been",
      "url": "https://finnhub.io/api/news?id=725bba216f3629ddc9248ae42d16a34e476c6b9e6f9a5b02d1ebe1ade0fced70"
    }
  },
  {
    "ts": null,
    "headline": "Merck: voluntary withdrawal of a BLA in lung cancer",
    "summary": "Merck and its partner Daiichi Sankyo announce the voluntary withdrawal of their Biologics License Application seeking accelerated approval in the US for their patritumab deruxtecan .The drug was...",
    "url": "https://finnhub.io/api/news?id=dc822ff41020ad46e7c57e7bd08e21e3c2133fec13277f3c4911030122e86972",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748512748,
      "headline": "Merck: voluntary withdrawal of a BLA in lung cancer",
      "id": 134808907,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck and its partner Daiichi Sankyo announce the voluntary withdrawal of their Biologics License Application seeking accelerated approval in the US for their patritumab deruxtecan .The drug was...",
      "url": "https://finnhub.io/api/news?id=dc822ff41020ad46e7c57e7bd08e21e3c2133fec13277f3c4911030122e86972"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Daiichi Sankyo Withdraw Application Seeking FDA Nod for ADC",
    "summary": "By Colin Kellaher Merck & Co. and Daiichi Sankyo have pulled an application seeking accelerated Food and Drug Administration approval of one of the drug candidates in their multibillion-dollar...",
    "url": "https://finnhub.io/api/news?id=a84d70c445e0d433d3194167e7597ee806942dd3829c965ad8c603cac97fa8c9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748507409,
      "headline": "Merck, Daiichi Sankyo Withdraw Application Seeking FDA Nod for ADC",
      "id": 134803712,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. and Daiichi Sankyo have pulled an application seeking accelerated Food and Drug Administration approval of one of the drug candidates in their multibillion-dollar...",
      "url": "https://finnhub.io/api/news?id=a84d70c445e0d433d3194167e7597ee806942dd3829c965ad8c603cac97fa8c9"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer",
    "summary": "Merck and Japan-based DaiichiSankyo have withdrawn their U.S. application for anexperimental lung cancer treatment after it failed to prolongthe lives of patients in a late-stage study, the...",
    "url": "https://finnhub.io/api/news?id=385215a7e4af1e0272c54cf8ca89fceca7d3f7866e9ccf23049383f9ab3a3076",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748503807,
      "headline": "Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer",
      "id": 134804815,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck and Japan-based DaiichiSankyo have withdrawn their U.S. application for anexperimental lung cancer treatment after it failed to prolongthe lives of patients in a late-stage study, the...",
      "url": "https://finnhub.io/api/news?id=385215a7e4af1e0272c54cf8ca89fceca7d3f7866e9ccf23049383f9ab3a3076"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Daiichi pull US application for 'guided missile' drug for lung cancer",
    "summary": "Merck and Japan-based DaiichiSankyo have withdrawn their U.S. application for anexperimental lung cancer treatment after it failed to prolongpatients' lives in a late-stage study, the companies...",
    "url": "https://finnhub.io/api/news?id=4981408b174f5a4dfff17d5935c544bc90bf813fd478dc8880b844f3a3119bd2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748503807,
      "headline": "Merck, Daiichi pull US application for 'guided missile' drug for lung cancer",
      "id": 134801720,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck and Japan-based DaiichiSankyo have withdrawn their U.S. application for anexperimental lung cancer treatment after it failed to prolongpatients' lives in a late-stage study, the companies...",
      "url": "https://finnhub.io/api/news?id=4981408b174f5a4dfff17d5935c544bc90bf813fd478dc8880b844f3a3119bd2"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Daiichi withdraw US application for 'guided missile' cancer drug",
    "summary": "Merck and Japan-based DaiichiSankyo said on Thursday they have withdrawn the U.S.application for an experimental lung cancer treatment, whichbelongs to a lucrative class of cancer therapies that...",
    "url": "https://finnhub.io/api/news?id=cd151b0a5de6bc0d331422c7b635a99a7dcde71c986508f2df6c38620522a34e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748502667,
      "headline": "Merck, Daiichi withdraw US application for 'guided missile' cancer drug",
      "id": 134801588,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck and Japan-based DaiichiSankyo said on Thursday they have withdrawn the U.S.application for an experimental lung cancer treatment, whichbelongs to a lucrative class of cancer therapies that...",
      "url": "https://finnhub.io/api/news?id=cd151b0a5de6bc0d331422c7b635a99a7dcde71c986508f2df6c38620522a34e"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial, conducted with Abbisko Therapeutics, showed a 61.9% overall response rate (ORR) by tumour volume score (TVS) after 25 weeks, far surpassing placebo (3.2%). This efficacy outperformed […]",
    "url": "https://finnhub.io/api/news?id=b63274a58960d8a5000977909785af2f23e52d22fa59b8169ce95f36f33e114a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748492975,
      "headline": "Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results",
      "id": 134812102,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial, conducted with Abbisko Therapeutics, showed a 61.9% overall response rate (ORR) by tumour volume score (TVS) after 25 weeks, far surpassing placebo (3.2%). This efficacy outperformed […]",
      "url": "https://finnhub.io/api/news?id=b63274a58960d8a5000977909785af2f23e52d22fa59b8169ce95f36f33e114a"
    }
  }
]